;)
Orphan Drugs and Rare Diseases: The Trial Design Paradox
Seventy-seven percent of drugs for rare diseases with pivotal efficacy data have orphan designations, and most are approved with Phase III randomized controlled trials (Domike et al, 2024). This creates a regulatory paradox: FDA rules permit Phase II approval with post-marketing commitment data, yet sponsors conduct resource-intensive Phase III trials anyway.
Why design larger, longer trials when regulatory pathways support accelerated approval on smaller Phase II data? In practice, formal regulatory flexibility often meets case-by-case conservatism. For example, gene therapy sponsors developing treatments for Leber hereditary optic neuropathy (LHON) have faced FDA requests for randomized, placebo-controlled Phase III trials despite investigator and patient arguments that such designs are ethically challenging—reflecting concerns about disease heterogeneity, spontaneous improvement in some patients, and difficulties curating suitable natural history controls (FDA, 2023).
Risk mitigation explains part of the paradox. Orphan drug approvals based on Phase II data carry an implicit commitment for post-marketing evidence collection. Conditional or accelerated approvals involve regulatory risk—if post-marketing data don’t support initial efficacy claims, the FDA can impose restrictive conditions, require additional data, or withdraw approval (Barbui et al., 2024). However, from a sponsor and investor perspective, conditional approval offers earlier market entry, revenue generation to support post-marketing studies, and potentially negotiable post-marketing commitments. For small biotechs, speed to a value-inflection point often outweighs long-term evidence risk, particularly when approval enables company sale or licensing deals.
Payers compound this conservatism. Sponsors conducting Phase II trials report criticism from payers regarding trial design, endpoint selection, and evidence robustness. Health technology assessment (HTA) processes in Europe often function as pricing negotiation mechanisms rather than purely scientific gatekeepers. In many markets, HTA criticism of orphan drugs reflects cost-effectiveness thresholds that make high-priced orphan therapies appear “not cost-effective” regardless of clinical evidence quality (Young et al., 2017). For sponsors, the dominant commercial focus is often on US and major EU markets and investor expectations for rapid progress, with HTA bodies less central to strategic decision-making. Sponsors have learned that generating Phase III data pre-emptively addresses anticipated payer objections, even when regulatory approval doesn’t require it.
The real constraint is sample size heterogeneity. Rare disease populations are dispersed, genetically heterogeneous, and biologically variable. Small sample sizes (n=20-50 or fewer for ultra-rare conditions) create statistical noise even in well-designed trials. Payers and clinicians recognize that this variability doesn’t reflect drug efficacy variability—it reflects population heterogeneity and natural history patterns, including spontaneous improvement in some diseases (Pizzamiglio et al., 2022). Addressing this skepticism requires either larger trials that reduce noise per patient, or different trial designs altogether – adaptive trials, external control arms, etc (Pizzamiglio et al., 2022).
Emerging Alternatives Gaining Traction
Adaptive designs: Pre-specifying interim analysis points, biomarker-driven patient enrichment, and dose-optimization procedures enable sponsors to reach efficacy conclusions with smaller total sample sizes while maintaining statistical rigor. Examples include seamless Phase II/III designs and group sequential designs with early stopping rules for futility or efficacy, which have been used in rare metabolic and hematologic disorders (Pizzamiglio et al., 2022).
External controls: Real-world data, natural history cohorts, and historical control arms provide context when randomization is ethically problematic (few patients means denying treatment is difficult) or logistically infeasible. FDA and EMA guidance increasingly accept external controls for orphan drug approvals when real-world evidence (RWE) is curated appropriately (FDA, 2023; Jahanshahi et al., 2021). However, regulatory acceptance of external controls remains highly case dependent. In Duchenne muscular dystrophy (DMD), rigorous multi-institutional natural history data have been validated as suitable for external control comparisons, supporting several approvals (Jahanshahi et al., 2021). In conditions with substantial heterogeneity or spontaneous remission (e.g., LHON), regulators have been more reluctant to rely solely on external controls. FDA’s 2023 draft guidance on externally controlled trials indicates growing but cautious openness, particularly for ultra-rare genetic diseases with well-characterized pathophysiology (FDA, 2023).
However, in many gene therapy and complex orphan trials (e.g., metachromatic leukodystrophy, spinal muscular atrophy), the operational reality has involved centralized, high-intensity trial conduct with families relocated to specialized centers for extended periods at sponsor expense, reflecting regulatory and procedural requirements for standardized, rigorous assessments (Pizzamiglio et al., 2022). Remote assessments and digital tools are being explored for long-term follow-up and patient-reported outcomes but rarely replace core central site visits entirely.
The unresolved tension: Regulatory bodies and payers incentivize different trial designs. FDA approves on Phase II data (FDA, 2023); payers prefer Phase III datasets (Young et al, 2017); clinical programs optimize for regulatory certainty even when it contradicts economic efficiency. This misalignment is compounded by the central role of patient organizations in rare diseases. Patient advocacy groups often influence endpoint selection, support recruitment and retention, and push back against trial designs perceived as unethical, such as prolonged placebo arms in rapidly progressive pediatric diseases (Confidence Research, 2024). For sponsors, particularly small biotechs, the strategic priority is often speed to value-inflection points for investors—first randomized data, first regulatory filing—with long-term pricing and HTA concerns deferred to acquirers.
Companies navigating this landscape will win by building trial designs that simultaneously satisfy regulatory, clinical and commercial objectives – and that integrate patient and family perspectives early in trial design (Confidence Research, 2024) – not by choosing one priority over others.
References
Confidence Research. (2024). The role of patient organizations in rare disease trials. Retrieved January 13, 2026, from https://confidenceresearch.com/the-role-of-patient-organizations-in-rare-disease-trials/
Domike, R., Raju, G. K., Sullivan, J., & Kennedy, A. (2024). Expediting treatments in the 21st century: Orphan drugs and accelerated approvals. Orphanet Journal of Rare Diseases, 19(1), 418.
Jahanshahi, M., et al. (2021). The use of external controls in FDA regulatory decision making. Therapeutic Innovation & Regulatory Science, 55(5), 1019–1035.
Jommi, C., Bonfanti, M., & et al. (2025). Pivotal studies for drugs about to be launched for rare diseases: Will they better support health technology assessment and market access than in the past? Journal of Market Access & Health Policy, 13(3), 37.
Pizzamiglio, C., et al. (2022). Designing clinical trials for rare diseases: What have we learnt? Pharmaceutical Medicine, 36, 121–136.
U.S. Food and Drug Administration. (2023, March). Considerations for the design and conduct of externally controlled trials for drug and biological products: Draft guidance. https://www.fda.gov/media/164960/download
U.S. Food and Drug Administration. (2023). Fast track breakthrough therapy, accelerated approval, priority review. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review
Young, K. E., et al. (2017). A comparative study of orphan drug prices in Europe. Health Policy, 121(10), 1050–1058.
